Make me an Anki card for [ALL] in the following format: Output ONLY a raw single line (no explanation, no code block markers, no extra text) where: - Front and Back are separated by a TAB character - Front = "[TOPIC] – Complete Pathology (NEET PG 2026)" - Back = fully detailed HTML using only <b>, <br>, <i> tags - Cover: definition, genetic/molecular basis, pathophysiology step by step, organ pathology, clinical features, lab findings, peripheral smear, diagnosis, differentials, management based on pathology, and exam pearls - End with a NEET PG one-liners section - Anki import settings: Tab separator, Field 1 = Front, Field 2 = Back, Allow HTML ON
Reading Document
Medical Text Search
Acute Lymphoblastic Leukemia ALL pathology genetics molecular basis classification
Medical Text Search
ALL diagnosis peripheral smear bone marrow lab findings management treatment
GradeResponse
GradeResponse
[ALL] – Complete Pathology (NEET PG 2026) Definition
Acute Lymphoblastic Leukemia (ALL) is a malignant neoplasm of lymphoid precursor cells (B- or T-lymphoblasts) characterized by clonal proliferation of immature blasts in bone marrow, blood, and extramedullary sites, causing marrow failure and tissue infiltration.
Genetic / Molecular Basis
Common cytogenetic/molecular lesions:
Favorable (especially pediatric B-ALL): Hyperdiploidy (>50 chromosomes), t(12;21) ETV6-RUNX1.
High risk / adverse: t(9;22) BCR-ABL1 (Philadelphia+), KMT2A (MLL) rearrangements (e.g., t(4;11)), hypodiploidy, complex karyotype, iAMP21.
T-ALL associated: NOTCH1 pathway alterations, TAL1/LMO dysregulation.
Pathogenic themes: Block in differentiation + unchecked proliferation + survival signaling activation.
Pathophysiology (Step by Step)
1) Genetic hit occurs in lymphoid progenitor in marrow.
2) Differentiation arrest at lymphoblast stage.
3) Clonal blast expansion replaces normal hematopoiesis.
4) Marrow failure develops:
Anemia -> pallor, fatigue
Thrombocytopenia -> petechiae, mucosal bleed
Neutropenia -> recurrent infections
5) Blasts spill into blood (variable WBC count).
6) Extramedullary infiltration: liver, spleen, lymph nodes, CNS, testes, mediastinum (esp. T-ALL).
7) High cell turnover may cause hyperuricemia and tumor lysis risk (spontaneous or post-therapy).
Organ Pathology
Bone marrow: Hypercellular marrow with lymphoblast predominance (classically >=20% blasts for acute leukemia diagnosis framework).
Lymph nodes/spleen/liver: Infiltration causing lymphadenopathy, hepatosplenomegaly.
Thymus/mediastinum: T-ALL may present with mediastinal mass.
CNS: Meningeal leukemic infiltration (headache, vomiting, cranial signs).
Testes: Sanctuary site, possible relapse focus.
Clinical Features
Marrow failure triad: Fatigue/pallor, fever/infections, bleeding manifestations.
Infiltrative features: Bone pain, lymphadenopathy, hepatosplenomegaly.
T-ALL clues: Adolescent male, mediastinal mass, possible SVC compression symptoms.
CNS disease: Headache, vomiting, cranial neuropathies.
Lab Findings
CBC: Anemia + thrombocytopenia; WBC low/normal/high.
Peripheral blood: Circulating blasts, neutropenia common.
Biochemistry: Elevated LDH, uric acid; possible electrolyte derangements in tumor lysis.
Bone marrow aspirate/biopsy: Lymphoblast-rich marrow.
Flow cytometry:
B-ALL: TdT+, CD10 (CALLA)+, CD19+, CD22+, CD79a+.
T-ALL: TdT+, cytoplasmic/surface CD3+, CD7+, often CD2/CD5.
Cytogenetics/molecular: Mandatory for risk stratification and targeted therapy planning.
Peripheral Smear
Lymphoblasts: small to medium cells, high N:C ratio, scant basophilic cytoplasm, fine chromatin, inconspicuous nucleoli (variable).
Auer rods absent (helps against AML).
Background: thrombocytopenia, anemia features.
Diagnosis
Integrated diagnosis requires:
1) Morphology (blood + marrow blasts)
2) Immunophenotyping (flow cytometry lineage assignment)
3) Cytogenetic/molecular profiling (risk and therapy)
4) Baseline staging for CNS/testicular/mediastinal disease where indicated.
MRD (minimal residual disease) monitoring is a major prognostic tool and guides response-adapted therapy.
Differentials
AML: Myeloblast markers (MPO+), Auer rods may be present.
Leukemoid reaction/infection: reactive cells, no clonal blast immunophenotype.
Lymphoblastic lymphoma: primarily mass lesion with limited marrow involvement (overlap entity).
Aplastic anemia: pancytopenia without blast proliferation.
Infectious mononucleosis: atypical lymphocytes, different clinical-lab context.
Management Based on Pathology
Core principle: Multi-agent risk-adapted chemotherapy + CNS-directed therapy + MRD-guided decisions.
Phases:
1) Induction: achieve complete remission (steroid + vincristine + asparaginase +/- anthracycline, protocol-dependent).
2) Consolidation/intensification: eradicate residual disease.
3) Maintenance: prolonged lower-intensity therapy (classically includes 6-MP + methotrexate based regimens).
CNS prophylaxis: Intrathecal chemotherapy +/- cranial irradiation in selected high-risk settings.
Targeted therapy: Ph+ ALL -> add tyrosine kinase inhibitor (e.g., imatinib/dasatinib) with chemotherapy backbone.
Relapsed/refractory: blinatumomab (CD19), inotuzumab ozogamicin (CD22), CAR-T (selected B-ALL), allogeneic stem cell transplant in high-risk or relapsed settings.
Supportive pathology-linked care: transfusions, infection prophylaxis/treatment, tumor lysis prevention (hydration, allopurinol/rasburicase), monitoring organ toxicity.
Exam Pearls (High Yield)
ALL is the most common childhood leukemia.
Commonest subtype is precursor B-ALL; T-ALL often presents with mediastinal mass.
Bone pain + cytopenias + blasts in child -> think ALL first.
TdT positivity supports lymphoblast origin.
Philadelphia chromosome in ALL implies poorer risk but targetable with TKIs.
Testes and CNS are sanctuary sites -> mandatory CNS-directed therapy and careful relapse surveillance.
MRD status after induction is one of the strongest prognostic indicators.
NEET PG One-Liners
Most common childhood malignancy leukemia: ALL.
Marker of lymphoblasts: TdT.
CALLA corresponds to: CD10 (B-ALL).
Mediastinal mass in acute leukemia suggests: T-ALL.
Auer rods favor: AML, not ALL.
Good prognostic cytogenetics in pediatric ALL: Hyperdiploidy, t(12;21).
Poor prognostic lesion classically tested: t(9;22) BCR-ABL1.
Sanctuary sites in ALL: CNS and testes.
Most important modern prognostic response marker: MRD.
Acute Lymphoblastic Leukemia (ALL) is a malignant neoplasm of lymphoid precursor cells (B- or T-lymphoblasts) characterized by clonal proliferation of immature blasts in bone marrow, blood, and extramedullary sites, causing marrow failure and tissue infiltration.
Genetic / Molecular Basis
Common cytogenetic/molecular lesions:
Favorable (especially pediatric B-ALL): Hyperdiploidy (>50 chromosomes), t(12;21) ETV6-RUNX1.
High risk / adverse: t(9;22) BCR-ABL1 (Philadelphia+), KMT2A (MLL) rearrangements (e.g., t(4;11)), hypodiploidy, complex karyotype, iAMP21.
T-ALL associated: NOTCH1 pathway alterations, TAL1/LMO dysregulation.
Pathogenic themes: Block in differentiation + unchecked proliferation + survival signaling activation.
Pathophysiology (Step by Step)
1) Genetic hit occurs in lymphoid progenitor in marrow.
2) Differentiation arrest at lymphoblast stage.
3) Clonal blast expansion replaces normal hematopoiesis.
4) Marrow failure develops:
Anemia -> pallor, fatigue
Thrombocytopenia -> petechiae, mucosal bleed
Neutropenia -> recurrent infections
5) Blasts spill into blood (variable WBC count).
6) Extramedullary infiltration: liver, spleen, lymph nodes, CNS, testes, mediastinum (esp. T-ALL).
7) High cell turnover may cause hyperuricemia and tumor lysis risk (spontaneous or post-therapy).
Organ Pathology
Bone marrow: Hypercellular marrow with lymphoblast predominance (classically >=20% blasts for acute leukemia diagnosis framework).
Lymph nodes/spleen/liver: Infiltration causing lymphadenopathy, hepatosplenomegaly.
Thymus/mediastinum: T-ALL may present with mediastinal mass.
CNS: Meningeal leukemic infiltration (headache, vomiting, cranial signs).
Testes: Sanctuary site, possible relapse focus.
Clinical Features
Marrow failure triad: Fatigue/pallor, fever/infections, bleeding manifestations.
Infiltrative features: Bone pain, lymphadenopathy, hepatosplenomegaly.
T-ALL clues: Adolescent male, mediastinal mass, possible SVC compression symptoms.
CNS disease: Headache, vomiting, cranial neuropathies.
Lab Findings
CBC: Anemia + thrombocytopenia; WBC low/normal/high.
Peripheral blood: Circulating blasts, neutropenia common.
Biochemistry: Elevated LDH, uric acid; possible electrolyte derangements in tumor lysis.
Bone marrow aspirate/biopsy: Lymphoblast-rich marrow.
Flow cytometry:
B-ALL: TdT+, CD10 (CALLA)+, CD19+, CD22+, CD79a+.
T-ALL: TdT+, cytoplasmic/surface CD3+, CD7+, often CD2/CD5.
Cytogenetics/molecular: Mandatory for risk stratification and targeted therapy planning.
Peripheral Smear
Lymphoblasts: small to medium cells, high N:C ratio, scant basophilic cytoplasm, fine chromatin, inconspicuous nucleoli (variable).
Auer rods absent (helps against AML).
Background: thrombocytopenia, anemia features.
Diagnosis
Integrated diagnosis requires:
1) Morphology (blood + marrow blasts)
2) Immunophenotyping (flow cytometry lineage assignment)
3) Cytogenetic/molecular profiling (risk and therapy)
4) Baseline staging for CNS/testicular/mediastinal disease where indicated.
MRD (minimal residual disease) monitoring is a major prognostic tool and guides response-adapted therapy.
Differentials
AML: Myeloblast markers (MPO+), Auer rods may be present.
Leukemoid reaction/infection: reactive cells, no clonal blast immunophenotype.
Lymphoblastic lymphoma: primarily mass lesion with limited marrow involvement (overlap entity).
Aplastic anemia: pancytopenia without blast proliferation.
Infectious mononucleosis: atypical lymphocytes, different clinical-lab context.
Management Based on Pathology
Core principle: Multi-agent risk-adapted chemotherapy + CNS-directed therapy + MRD-guided decisions.
Phases:
1) Induction: achieve complete remission (steroid + vincristine + asparaginase +/- anthracycline, protocol-dependent).
2) Consolidation/intensification: eradicate residual disease.
3) Maintenance: prolonged lower-intensity therapy (classically includes 6-MP + methotrexate based regimens).
CNS prophylaxis: Intrathecal chemotherapy +/- cranial irradiation in selected high-risk settings.
Targeted therapy: Ph+ ALL -> add tyrosine kinase inhibitor (e.g., imatinib/dasatinib) with chemotherapy backbone.
Relapsed/refractory: blinatumomab (CD19), inotuzumab ozogamicin (CD22), CAR-T (selected B-ALL), allogeneic stem cell transplant in high-risk or relapsed settings.
Supportive pathology-linked care: transfusions, infection prophylaxis/treatment, tumor lysis prevention (hydration, allopurinol/rasburicase), monitoring organ toxicity.
Exam Pearls (High Yield)
ALL is the most common childhood leukemia.
Commonest subtype is precursor B-ALL; T-ALL often presents with mediastinal mass.
Bone pain + cytopenias + blasts in child -> think ALL first.
TdT positivity supports lymphoblast origin.
Philadelphia chromosome in ALL implies poorer risk but targetable with TKIs.
Testes and CNS are sanctuary sites -> mandatory CNS-directed therapy and careful relapse surveillance.
MRD status after induction is one of the strongest prognostic indicators.
NEET PG One-Liners
Most common childhood malignancy leukemia: ALL.
Marker of lymphoblasts: TdT.
CALLA corresponds to: CD10 (B-ALL).
Mediastinal mass in acute leukemia suggests: T-ALL.
Auer rods favor: AML, not ALL.
Good prognostic cytogenetics in pediatric ALL: Hyperdiploidy, t(12;21).
Poor prognostic lesion classically tested: t(9;22) BCR-ABL1.
Sanctuary sites in ALL: CNS and testes.
Most important modern prognostic response marker: MRD.
This is a shared conversation. Sign in to Orris to start your own chat.